Int. J. Mol. Sci. 2017, 18(8), 1658; https://doi.org/10.3390/ijms18081658
TGFβ Controls Ovarian Cancer Cell Proliferation
Elisenda Alsina-Sanchís 1,2, Agnès Figueras 1,2, Alvaro Lahiguera 1,2, Marta Gil-Martín 2,3
, Beatriz Pardo 2,3, Josep M. Piulats 2,3, Lola Martí 2,4, Jordi Ponce 2,4, Xavier Matias-Guiu 2,5, August Vidal 2,5,6,7, Alberto Villanueva 1,2,6 and Francesc Viñals 1,2,8,*
, Beatriz Pardo 2,3, Josep M. Piulats 2,3, Lola Martí 2,4, Jordi Ponce 2,4, Xavier Matias-Guiu 2,5, August Vidal 2,5,6,7, Alberto Villanueva 1,2,6 and Francesc Viñals 1,2,8,*
1
Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d’Oncologia, Hospital Duran i Reynals, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
2
Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain
3
Medical Oncology Department, Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
4
Gynaecologic Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
5
Servei d’Anatomia Patològica, Hospital Universitari de Bellvitge, CIBERONC, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
6
Xenopat, Carrer de la Feixa Llarga S/N, L'Hospitalet de Llobregat, 08907 Barcelona, Spain
7
Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
8
Departament de Ciències Fisiològiques, Universitat de Barcelona, L’Hospitalet de Llobregat, 08908 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Received: 7 June 2017 / Revised: 17 July 2017 / Accepted: 24 July 2017 / Published: 30 July 2017
(This article belongs to the Special Issue TGF-beta Family in Fibrosis and Cancer)
Abstract
There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development. View Full-TextKeywords:
TGFβ; ovarian cancer; IGF1R; proliferation
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Alsina-Sanchís, E.; Figueras, A.; Lahiguera, A.; Gil-Martín, M.; Pardo, B.; Piulats, J.M.; Martí, L.; Ponce, J.; Matias-Guiu, X.; Vidal, A.; Villanueva, A.; Viñals, F. TGFβ Controls Ovarian Cancer Cell Proliferation. Int. J. Mol. Sci. 2017, 18, 1658.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert